Betta Pharma Licenses Inventisbio’s D-0316 to Treat Non-Small Cell Lung Cancer (NSCLC)

 Betta Pharma Licenses Inventisbio’s D-0316 to Treat Non-Small Cell Lung Cancer (NSCLC)

Betta Pharma Licenses Inventisbio’s D-0316 to Treat Non-Small Cell Lung Cancer (NSCLC)

Shots:
  • InventisBio to receive 36.4M including upfront, sales and R&D milestone and royalties on sales and will co-develop D-0316 in China with Betta Pharma. Betta Pharma to get exclusive commercialization rights of D-0316 in China, Hong Kong and Taiwan
  • The focus of the agreement is to expand and strengthen Betta Pharma’s portfolio in lung cancer treatment
  • InventisBio’s D-0316 is a third-generation EGFR-T790M tyrosine kinase inhibitor, evaluated in P-I for the treatment of EGFR-mutant NSCLC in China

Click here to read full press release/ article | Ref: Prnewswire | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post